Premium
Baricitinib: a new oral treatment for rheumatoid arthritis
Author(s) -
Chaplin Steve
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1586
Subject(s) - medicine , rheumatoid arthritis , janus kinase inhibitor , janus kinase , dermatology , tofacitinib , receptor
Baricitinib (Olumiant) is a new oral janus kinase inhibitor licensed for the second‐line treatment of moderate to severe active rheumatoid arthritis. This article summarises its efficacy, side‐effects and place in therapy.